ArticleThe Kaohsiung journal of medical sciences2026
Diagnostic Accuracy of Serum-Based Fibrosis Scores for Clinically Significant Liver Fibrosis in an East Asian Cohort.
Article in The Kaohsiung journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Serum-based fibrosis scores are widely used for noninvasive risk stratification in chronic liver disease; however, direct comparisons across liver disease etiologies remain limited, particularly in Asian populations with a high prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. This study retrospectively analyzed the data of adults who underwent transient elastography (FibroScan) at a university-affiliated hospital. Three fibrosis scores were evaluated: Fibrosis-4 index (FIB-4), aspartate aminotransferase-to-platelet ratio index (APRI), and metabolic dysfunction-associated fibrosis-5 (MAF-5). Associations with advanced fibrosis (F3-F4) were examined using logistic regression. Discrimination was assessed using the area under the receiver operating characteristic curve (AUROC). Of the 2355 participants, the etiologic subgroups included metabolic dysfunction-associated steatotic liver disease (MASLD; n = 1070), HBV infection (n = 1459), and HCV infection (n = 250); 10.4% of the participants had advanced fibrosis (F3-F4). In the overall cohort, all scores were significantly associated with advanced fibrosis (p < 0.001) and demonstrated similar overall discrimination with AUROC in a range of 0.824-0.839. MAF-5 had the highest AUROC (0.839; 95% confidence interval [CI], 0.811-0.867) and greater risk classification compared with FIB-4 (net reclassification improvement = 0.168; 95% CI, 0.093-0.244). Subgroup analysis revealed that MAF-5 exhibited consistent discrimination across etiologies, with AUROCs of 0.822 (0.781-0.863) in MASLD, 0.843 (95% CI, 0.804-0.882) in HBV, and 0.810 (95% CI, 0.735-0.886) in HCV. Commonly used serum-based fibrosis scores exhibited comparable discrimination for advanced fibrosis. However, the metabolically informed MAF-5 score modestly improved risk classification across diverse liver disease etiologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.